Literature DB >> 8090389

Safety of the new quinolones in pregnancy.

M Berkovitch1, A Pastuszak, M Gazarian, M Lewis, G Koren.   

Abstract

OBJECTIVE: To investigate the effect on the fetus of intrauterine exposure to quinolones in terms of teratogenicity, with special focus on the musculoskeletal system.
METHODS: We studied 38 pregnant women who received quinolones and consulted the Motherisk Program in Toronto from 1989-1992. Perinatal complications, birth weight, birth defects, and developmental milestones, with particular emphasis on the musculoskeletal system, were compared with those of controls matched for both maternal age and indication for antibacterial therapy.
RESULTS: Thirty-five women (92%) treated with norfloxacin or ciprofloxacin received therapy during the first trimester. The most common indication for therapy (92%) was urinary tract infection. More pregnancies in the quinolone group resulted in cesarean delivery due to reported fetal distress as compared to the controls (P = .005), without clear reason. Children born to mothers treated with quinolones were significantly heavier (P = .05) than the control infants, possibly because of better control of the urinary tract infection. No malformations were found in the quinolone group, whereas one child in the control group had a ventricular septal defect. No differences were detected between the groups in achievement of developmental milestones or in the musculoskeletal system.
CONCLUSION: The use of the new quinolones during the first trimester of pregnancy does not appear to be associated with an increased risk of malformations or musculoskeletal problems; however, longer follow-up and magnetic resonance imaging of the joints may be warranted to exclude subtle cartilage and bone damage.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8090389

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  20 in total

Review 1.  Inflammatory bowel disease in pregnancy.

Authors:  E M Alstead
Journal:  Postgrad Med J       Date:  2002-01       Impact factor: 2.401

Review 2.  Fertility and pregnancy in inflammatory bowel disease.

Authors:  E Alstead
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  Treatment of Stenotrophomonas neonatal urinary tract infection with instillation of ciprofloxacin.

Authors:  Mohammad Khassawneh; Wail Hayajneh
Journal:  Pediatr Nephrol       Date:  2010-02-18       Impact factor: 3.714

Review 4.  IBD and Pregnancy.

Authors:  Audrey H Calderwood; Sunanda V Kane
Journal:  MedGenMed       Date:  2004-10-08

5.  Use of the new quinolones during pregnancy.

Authors:  G Koren
Journal:  Can Fam Physician       Date:  1996-06       Impact factor: 3.275

6.  Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones.

Authors:  Stephanie Padberg; Evelin Wacker; Reinhard Meister; Mary Panse; Corinna Weber-Schoendorfer; Marc Oppermann; Christof Schaefer
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

Review 7.  Challenges in interventional radiology: the pregnant patient.

Authors:  Eunice K Moon; Weiping Wang; James S Newman; Maria Del Pilar Bayona-Molano
Journal:  Semin Intervent Radiol       Date:  2013-12       Impact factor: 1.513

8.  Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study.

Authors:  Flory T Muanda; Odile Sheehy; Anick Bérard
Journal:  Br J Clin Pharmacol       Date:  2017-08-11       Impact factor: 4.335

Review 9.  Diagnosis and treatment of allergic rhinitis and sinusitis during pregnancy and lactation.

Authors:  Gary A Incaudo
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

10.  Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study.

Authors:  R Loebstein; A Addis; E Ho; R Andreou; S Sage; A E Donnenfeld; B Schick; M Bonati; M Moretti; A Lalkin; A Pastuszak; G Koren
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.